Free Trial

Entropy Technologies LP Purchases Shares of 22,501 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics logo with Medical background

Key Points

  • Entropy Technologies LP acquired 22,501 shares of Sarepta Therapeutics, valued at approximately $1.4 million, in the first quarter, highlighting institutional interest in the stock.
  • Sarepta Therapeutics reported better-than-expected earnings of $2.02 per share for the last quarter, significantly surpassing analysts' estimates, and a 68.4% increase in year-over-year revenue.
  • The stock has a consensus rating of "Hold" among analysts, with a current target price averaging around $44.17, amid diverse ratings from multiple financial institutions.
  • Need better tools to track Sarepta Therapeutics? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Entropy Technologies LP bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 22,501 shares of the biotechnology company's stock, valued at approximately $1,436,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. New York State Teachers Retirement System grew its stake in Sarepta Therapeutics by 3.3% in the first quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock valued at $5,065,000 after acquiring an additional 2,512 shares during the period. Exchange Traded Concepts LLC bought a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $479,000. GAMMA Investing LLC lifted its holdings in shares of Sarepta Therapeutics by 4,682.8% in the first quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock valued at $2,607,000 after purchasing an additional 39,991 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $821,000. Finally, Cetera Investment Advisers lifted its holdings in shares of Sarepta Therapeutics by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 11,174 shares of the biotechnology company's stock valued at $1,359,000 after purchasing an additional 463 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SRPT. BMO Capital Markets boosted their price target on Sarepta Therapeutics from $25.00 to $50.00 and gave the company a "market perform" rating in a report on Tuesday, July 29th. Morgan Stanley boosted their price target on Sarepta Therapeutics from $15.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, July 29th. Leerink Partnrs lowered Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. HC Wainwright reiterated a "sell" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. Finally, Robert W. Baird boosted their price target on Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Five analysts have rated the stock with a sell rating, seventeen have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $44.17.

View Our Latest Research Report on Sarepta Therapeutics

Sarepta Therapeutics Stock Performance

SRPT stock traded up $0.86 during midday trading on Tuesday, reaching $18.80. 7,536,464 shares of the company's stock traded hands, compared to its average volume of 23,381,442. The company has a 50-day moving average price of $20.93 and a two-hundred day moving average price of $55.53. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $144.22. The firm has a market capitalization of $1.84 billion, a PE ratio of -21.61 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business's revenue for the quarter was up 68.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.07 EPS. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Company Profile

(Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Featured Articles

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Should You Invest $1,000 in Sarepta Therapeutics Right Now?

Before you consider Sarepta Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.

While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines